Vertex Pharmaceuticals IncorporatedVRTXNASDAQ
Loading
Book Value/Share Growth AcceleratingAccelerating
Percentile Rank72
3Y CAGR+8.7%
5Y CAGR+4.1%
Year-over-Year Change
Year-over-year book value per share growth
3Y CAGR
+8.7%/yr
vs +23.9%/yr prior
5Y CAGR
+4.1%/yr
Recent acceleration
Acceleration
-15.1pp
Decelerating
Percentile
P72
Within normal range
vs 5Y Ago
1.2x
Modest growth
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 8.50% |
| Q3 2025 | 1.27% |
| Q2 2025 | 4.20% |
| Q1 2025 | 0.76% |
| Q4 2024 | 5.19% |
| Q3 2024 | 5.84% |
| Q2 2024 | -20.31% |
| Q1 2024 | 5.29% |
| Q4 2023 | 6.59% |
| Q3 2023 | 6.62% |
| Q2 2023 | 7.07% |
| Q1 2023 | 3.53% |
| Q4 2022 | 6.61% |
| Q3 2022 | 8.93% |
| Q2 2022 | 9.07% |
| Q1 2022 | 7.78% |
| Q4 2021 | 7.34% |
| Q3 2021 | 4.08% |
| Q2 2021 | 2.56% |
| Q1 2021 | 3.64% |
| Q4 2020 | 6.95% |
| Q3 2020 | 7.86% |
| Q2 2020 | 16.45% |
| Q1 2020 | 5.45% |
| Q4 2019 | 15.36% |
| Q3 2019 | 3.30% |
| Q2 2019 | 7.15% |
| Q1 2019 | 6.15% |
| Q4 2018 | 51.16% |
| Q3 2018 | 7.76% |
| Q2 2018 | 11.29% |
| Q1 2018 | 18.24% |
| Q4 2017 | 12.68% |
| Q3 2017 | -4.49% |
| Q2 2017 | 10.29% |
| Q1 2017 | 25.74% |
| Q4 2016 | 9.72% |
| Q3 2016 | 3.70% |
| Q2 2016 | 4.44% |
| Q1 2016 | 0.39% |